OBJECTIVE: Several features of bisphosphonate therapy for osteoporosis may influence patient satisfaction, including dosing convenience. The objective of this study was to evaluate the psychometric characteristics of the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q), which assesses patient satisfaction with osteoporosis treatment. METHODS: Patient focus groups and cognitive debriefings informed the development of the 16-item OPSAT-Q, which contains four subscales: Convenience, Confidence with Daily Activities, Side Effects and Overall Satisfaction. Both subscale scores and a composite score (CSS) can be calculated, with higher scores indicating greater satisfaction. The OPSAT-Q, Osteoporosis Targeted Quality of Life (OptQoL), three single-item global measures related to satisfaction, and demographic questionnaires were self-administered to eligible women recruited from four US clinics. Participants were diagnosed with osteoporosis or osteopenia and currently taking daily or weekly bisphosphonate treatment. Reproducibility was assessed via a follow-up questionnaire completed by participants two-weeks post baseline. Analyses included item and scale performance, internal consistency reliability, reproducibility, and construct validity. RESULTS: A total of 104 women with a mean age of 65 years participated. The majority was white (64.4%), living with someone (74%), and not currently employed (58.7%). On a scale of 0–100, individual patient subscale scores ranged from 17 to 100 and CSS scores ranged from 44-100. All scores showed acceptable internal consistency reliability (Cronbach's ? > 0.70) (range 0.72 to 0.89). Reproducibility exceeded 0.70 for all scores except Confidence with Daily Activity (0.62) and Overall Satisfaction (0.64). Significant correlations were found between the OPSAT-Q subscales and conceptually similar global measures (p<0.001). CONCLUSIONS: The findings from this study provide evidence of the validity and reliability of the OPSAT-Q and support the proposed composition of four subscales and a composite score. They also support the use of the OPSAT-Q to examine the impact of potentially more convenient bisphosphonate dosing on patient satisfaction.